Format

Send to

Choose Destination
Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12867-71.

Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma.

Author information

1
Department of Neurology, Children's Hospital, Boston, MA 02115.

Abstract

Medulloblastoma, the most common malignant brain tumor of childhood, has a variable prognosis. Although half of the children and young adults with the disease survive longer than 10 years after diagnosis, the others relapse and die despite identical therapy. We have examined the expression of neurotrophins and their receptors in medulloblastoma samples snap frozen in the operating room to preserve RNA integrity. All tumors (n = 12) were found to express mRNA encoding neurotrophin 3 and its receptor TrkC. The level of trkC expression was highly variable, with a more than 50-fold difference between the highest and lowest values. By Kaplan-Meier analysis, patients with tumors expressing high levels of trkC mRNA had significantly longer intervals without disease progression than those with low levels (log-rank, P = 0.03) and a more favorable overall survival (log-rank, P = 0.05). Thus, trkC expression is a prognostic indicator for patients with medulloblastoma.

PMID:
7809137
PMCID:
PMC45541
DOI:
10.1073/pnas.91.26.12867
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center